Ona Therapeutics is working on treatments for metastatic cancer and has collected series A funding from investors including Bpifrance.

Ona Therapeutics, a Spain-based cancer therapy developer spun out of ICREA and IRB Barcelona, has gathered €30m ($33.9m) in series A funding from backers such as French state-owned investment bank Bpifrance.
Asabys Partners, Alta Life Sciences, Fund+ and Ysios Capital also contributed to the round.
Founded in 2019, Ona Therapeutics is working on therapeutics that block the pathways which enable fat metabolism, in turn inhibiting cancer cells from metastasising.
The approach has been proven in animal models…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in